APA
Earl H. M., Hiller L., Dunn J. A., Vallier A., Bowden S. J., Jordan S. D., Blows F., Munro A., Bathers S., Grieve R., Spooner D. A., Agrawal R., Fernando I., Brunt A. M., O'Reilly S. M., Crawford S. M., Rea D. W., Simmonds P., Mansi J. L., Stanley A., McAdam K., Foster L., Leonard R. C. F., Twelves C. J., Cameron D., Bartlett J. M. S., Pharoah P., Provenzano E., Caldas C. & Poole C. J. (20121211). Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. : British journal of cancer.
Chicago
Earl H M, Hiller L, Dunn J A, Vallier A-L, Bowden S J, Jordan S D, Blows F, Munro A, Bathers S, Grieve R, Spooner D A, Agrawal R, Fernando I, Brunt A M, O'Reilly S M, Crawford S M, Rea D W, Simmonds P, Mansi J L, Stanley A, McAdam K, Foster L, Leonard R C F, Twelves C J, Cameron D, Bartlett J M S, Pharoah P, Provenzano E, Caldas C and Poole C J. 20121211. Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. : British journal of cancer.
Harvard
Earl H. M., Hiller L., Dunn J. A., Vallier A., Bowden S. J., Jordan S. D., Blows F., Munro A., Bathers S., Grieve R., Spooner D. A., Agrawal R., Fernando I., Brunt A. M., O'Reilly S. M., Crawford S. M., Rea D. W., Simmonds P., Mansi J. L., Stanley A., McAdam K., Foster L., Leonard R. C. F., Twelves C. J., Cameron D., Bartlett J. M. S., Pharoah P., Provenzano E., Caldas C. and Poole C. J. (20121211). Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. : British journal of cancer.
MLA
Earl H M, Hiller L, Dunn J A, Vallier A-L, Bowden S J, Jordan S D, Blows F, Munro A, Bathers S, Grieve R, Spooner D A, Agrawal R, Fernando I, Brunt A M, O'Reilly S M, Crawford S M, Rea D W, Simmonds P, Mansi J L, Stanley A, McAdam K, Foster L, Leonard R C F, Twelves C J, Cameron D, Bartlett J M S, Pharoah P, Provenzano E, Caldas C and Poole C J. Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. : British journal of cancer. 20121211.